Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23336744 | 1.00 | BTK (0.48) | BTKLCK | |
| SCHEMBL23304176 | 0.92 | BTK (0.51) | BTKLCK | |
| SCHEMBL23303855 | 0.92 | BTK (0.49) | BTKLCK | |
| SCHEMBL23304042 | 0.89 | BTK (0.48) | BTKLCK | |
| Trifluoroacetic Acid SCHEMBL23303807 | 0.88 | BTK (0.47) | BTKLCK | |
| Trifluoroacetic Acid SCHEMBL23303671 | 0.88 | BTK (0.46) | BTKLCK | |
| SCHEMBL23304119 | 0.88 | BTK (0.47) | BTKLCK | |
| SCHEMBL23303784 | 0.88 | BTK (0.47) | BTKLCK | |
| SCHEMBL23303937 | 0.88 | BTK (0.49) | BTKLCK | |
| SCHEMBL23336739 | 0.88 | BTK (0.49) | BTKLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | BTK 1/4885LCK 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.